1 week Ago By ABMN Staff
Athira Pharma, Inc. ( NASDAQ:ATHA – Get Free Report ) CEO Mark James Litton sold 25,107 shares of Athira Pharma stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $0.
56, for a total transaction of $14,059.92. Following the completion of the sale, the chief executive officer now owns 242,591 shares of the company’s stock, valued at $135,850.
96. This trade represents a 9.38 % decrease in their ownership of the stock.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink . Athira Pharma Price Performance NASDAQ ATHA opened at $0.57 on Friday.
The company’s fifty day moving average is $0.61 and its two-hundred day moving average is $1.50.
The firm has a market capitalization of $22.16 million, a price-to-earnings ratio of -0.20 and a beta of 2.
99. Athira Pharma, Inc. has a 52-week low of $0.
41 and a 52-week high of $4.30. Athira Pharma ( NASDAQ:ATHA – Get Free Report ) last issued its quarterly earnings results on Thursday, November 7th.
The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.
05. As a group, sell-side analysts expect that Athira Pharma, Inc. will post -2.
35 earnings per share for the current fiscal year. Wall Street Analyst Weigh In Read Our Latest Research Report on Athira Pharma Institutional Inflows and Outflows A number of large investors have recently modified their holdings of ATHA. Rothschild Investment LLC bought a new stake in Athira Pharma in the 2nd quarter valued at $34,000.
XTX Topco Ltd acquired a new stake in shares of Athira Pharma during the 2nd quarter valued at about $60,000. Invst LLC bought a new stake in Athira Pharma in the second quarter valued at about $68,000. American Century Companies Inc.
raised its position in Athira Pharma by 9.4% in the second quarter. American Century Companies Inc.
now owns 38,940 shares of the company’s stock worth $103,000 after purchasing an additional 3,333 shares in the last quarter. Finally, Forefront Analytics LLC lifted its stake in Athira Pharma by 126.0% during the second quarter.
Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after purchasing an additional 25,979 shares during the period. 57.12% of the stock is currently owned by institutional investors and hedge funds.
Athira Pharma Company Profile ( Get Free Report ) Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. Further Reading Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.
com's FREE daily email newsletter ..
